In last trading session, Abbvie Inc (NYSE:ABBV) saw 5.57 million shares changing hands with its beta currently measuring 0.62. Company’s recent per share price level of $188.86 trading at $0.29 or 0.15% at ring of the bell on the day assigns it a market valuation of $333.59B. That closing price of ABBV’s stock is at a discount of -5.87% from its 52-week high price of $199.95 and is indicating a premium of 28.07% from its 52-week low price of $135.85. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.54 million shares which gives us an average trading volume of 4.74 million if we extend that period to 3-months.

For Abbvie Inc (ABBV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.84. Splitting up the data highlights that, out of 27 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 7 suggested the stock as a Hold whereas 20 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Abbvie Inc (NYSE:ABBV) trade information

Upright in the green during last session for gaining 0.15%, in the last five days ABBV remained trading in the red while hitting it’s week-highest on Monday, 10/14/24 when the stock touched $188.86 price level, adding 3.81% to its value on the day. Abbvie Inc’s shares saw a change of 21.87% in year-to-date performance and have moved -2.74% in past 5-day. Abbvie Inc (NYSE:ABBV) showed a performance of -2.46% in past 30-days. Number of shares sold short was 14.86 million shares which calculate 3.15 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 171 to the stock, which implies a fall of -10.44% to its current value. Analysts have been projecting 127 as a low price target for the stock while placing it at a high target of 214. It follows that stock’s current price would jump 32.75% in reaching the projected high whereas dropping to the targeted low would mean a gain of 32.75% for stock’s current value.

Abbvie Inc (ABBV) estimates and forecasts

Statistics highlight that Abbvie Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 13.49% of value to its shares in past 6 months, showing an annual growth rate of -2.16% while that of industry is 6.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -5.77% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -2.20% while estimates for its earnings growth in next 5 years are of 8.10%.

ABBV Dividends

Abbvie Inc is more likely to be releasing its next quarterly report on 2024-Oct-30 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 3.28%, the share has a forward dividend of 6.20 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 4.19%.

Abbvie Inc (NYSE:ABBV)’s Major holders

Insiders are in possession of 0.09% of company’s total shares while institution are holding 73.32 percent of that, with stock having share float percentage of 73.39%. Investors also watch the number of corporate investors in a company very closely, which is 73.32% institutions for Abbvie Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at ABBV for having 170.66 million shares of worth $29.27 billion. And as of 2024-06-30, it was holding 9.6472 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 136.43 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7124 of outstanding shares, having a total worth of $23.4 billion.